TY  -  
T1  - Generation of a genetically modified oncolytic platform for cancer immunotherapy 
SN  -  /  
UR  - URN:NBN:fi-fe201801151403; http://hdl.handle.net/10138/236803 
T3  -  
A1  - Sjöberg, Madeleine 
A2  -  
PB  - Helsingfors universitet 
Y1  - 2018 
LA  - eng 
AB  - Cancer afflicts an ever-growing number of people globally each year. In part due to a complex pathophysiology where much is still unknown, the need for new cancer treatments has been persistent, fuelled further by the issue of treatment resistance. An emerging field holding much promise in oncology is immunotherapy, a subgroup of which is oncolytic virus treatments. These treatments utilize the inherent or acquired ability of certain viruses to selectively replicate in tumor cells to fight cance... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Gibson Assembly®; oncolytic adenovirus; CD40 ligand; genetic arming; homologous recombination; onkolyyttinen adenovirus; CD40 ligandi; geneettinen aseistaminen; homologinen rekombinaatio; Biofarmaci; Biopharmacy; Biofarmasia 
N1  -   
PP  -  
ER  -